Issues

Home > Issues (Page 13)

May 19, 2021 Industry Trends

There's dissension within House Democrats' ranks. Last week, no fewer than 10 House Democrats urged Speaker Nancy Pelosi to abandon H.R. 3, as the legislation is known, in favor of a more bipartisan approach that can "preserve our invaluable innovation ecosystem." Slapping new taxes and price controls on prescription drugs, as H.R. 3 would, has always been a bad idea — one that is guaranteed to undermine research into new drugs and vaccines. But it's borderline reckless to do so right as...

May 18, 2021 Price and Costs

Proponents from states such as California, Oregon, and Connecticut all claim that “pay for delay” legislation is necessary to rein in the pharmaceutical industry’s anti-competitive practices. If implemented, the bills will impose a high cost on patients by raising the costs of medicines and delaying generic entry into the market. Pay for delay tactics refers to the practice of patented drug manufacturers paying off generic manufacturers for the sole purpose of delaying the launch of competitive products. When successful, such tactics...

May 16, 2021 Industry Trends

How the New Price Transparency Rules are Affecting Stakeholders May 13, 2021 Deborah Abrams Kaplan Although the hospital price transparency final rule took effect in January, it will take time for it to get its sea legs, whether that means 100% hospital compliance, inspiring patients to use it for their own healthcare decisions or for hospitals to reevaluate their pricing based on their competition. Eventually, though, “I think it will open up the market and, hopefully, reduce the cost of healthcare,” says Sally...

May 16, 2021 Coronavirus-Alternate2

Medicare for All just won’t die. More than 100 House Democrats have signed onto new legislation that, if passed, would outlaw all private insurance and put all Americans on a federally run insurance plan within two years. The bill’s chief sponsor, Rep. Pramila Jayapal, D-Wash., says Medicare for All is the “solution” to the covid-19 crisis and will improve access to quality care in the long run. Health care is a human right, she says. She could hardly be more wrong. A...

May 16, 2021 Innovation, Issues, Price and Costs

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="2/3"][vc_column_text css=".vc_custom_1621192674245{padding-right: 40px !important;}"]DOWNLOAD THE PDF In October 2019, the Center for Medical Economics and Innovation at the Pacific Research Institute released its second study documenting the savings potential enabled by biosimilars. Biosimilars are medicines manufactured in, or derived from, biological sources that are developed to be similar to FDA-approved reference products. Biosimilars are approved to compete in nine biologic drug classes in the U.S., and are available in seven of these drug...

May 14, 2021 Industry Trends

Last year was the first year in which physicians working in private practice accounted for fewer than half of all practicing doctors, according to a new new report from the American Medical Association. Many of these formerly independent doctors went to work for big healthcare systems. That finding may sound obscure. Why should patients care whether a doctor draws his or her paycheck from a hospital or a private practice he or she owns? But the corporatization of medicine could be bad news for...

May 13, 2021 Coronavirus - Alternate

President Biden recently backed a World Trade Organization proposal to waive intellectual property protections on COVID-19 vaccines and therapies — a move the Trump administration rejected just a few months ago. The White House’s decision is a catastrophe. The waiver will do nothing to increase access to vaccines. It will, however, undermine the system of intellectual property protections that made these breakthrough vaccines possible. Patients today and well into the future will suffer, as investors think twice about funding risky efforts to research and develop therapies...

May 12, 2021 Industry Trends

By Henry Miller, M.S., M.D., and Kathleen Hefferon, Ph.D The controversy over genetically engineered organisms (sometimes called “genetically modified organisms,” or “GMOs”) is genuine, not faux — but only because of uninformed, exaggerated concerns about the most recent techniques’ “newness.” What is faux and disingenuous are the arguments put forth by genetic engineering’s opponents. Humans have been modifying the DNA of our food for thousands of years (even though we didn’t know that DNA was mediating the changes until the 20th century). We call...

May 11, 2021 Coronavirus-Alternate2

Dr. Henry Miller talks about the unintended and negative consequences of the Biden administration invalidating patents for COVID=19 vaccines. Dr. Miller explains that while removing patent rights will enable other companies and institutions to produce these vaccines, Biden and the U.S. should have focused on increased production to ship elsewhere. Miller says that vaccines are considered biologicals and are often difficult to manufacture and that these copies of the COVID-19 vaccines are "biosimiliars," which follow different rules and guidelines including...

May 10, 2021 Coronavirus

Don't throw those masks away just yet. Last week, the Centers for Disease Control and Prevention (CDC) relaxed mask-wearing guidance for those who have been fully vaccinated. But only outside. And only in settings that aren't crowded. However, the CDC could've issued much of this new guidance months ago. Epidemiologists have known since last summer that it's nearly impossible to contract the virus outdoors, even for an unvaccinated person. Waiting to ease mask restrictions is part and parcel of a doomsday mentality...

May 6, 2021 Innovation

By Henry Miller, M.S., M.D. and Andrew I. Fillat Sometimes the sheer stupidity, posturing, and lack of insight by policymakers are breathtaking. As a form of virtue signaling, the Biden administration has just announced U.S. support at the World Health Organization (under TRIPS, the Agreement on Trade-Related Aspects of Intellectual Property Rights) for waivers of patents on COVID-19 vaccines. Patents are widely misunderstood. They do not so much permit the holder to do something; rather, they prohibit others from copying the patented “invention,” and, thereby, can...

April 28, 2021 Industry Trends

By Robert Popovian, Pharm.D., MS, and Wayne Winegarden, Ph.D. Biologics are not natural monopolies, as certain individuals continually assert. This assertion threatens future innovations, greater healthcare affordability, and patient access. It is well understood that biologics have improved our ability to treat diseases such as cancer and autoimmune ailments. Biologics are also expensive; they now represent 43% of invoice spending, and spending has been growing 14.6% annually over the past five years. Until recently, originator biologics lacked any meaningful competition from less costly off-patent generic copies...

April 26, 2021 Coronavirus

Several European countries just instituted another round of lockdowns amid a new wave of Covid-19 cases. This turn of events is sobering but puzzling. Europe seemed to have Covid-19 under control a few months ago, at least compared to the United States. What happened? The countries' vaccination rates offer an explanation. Europe has inoculated far fewer people than the United States. So while Americans may enjoy some semblance of normalcy by summer, Europeans may face dark days ahead. Unfortunately, European countries can only blame themselves for their...

April 26, 2021 Blog, Policy Proposals

The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for the entire country. By statute, the government will base the negotiations on the prices charged in other nations. Since these nations impose stringent price controls on drugs, H.R. 3 is a...

April 21, 2021 Coronavirus-Alternate2

It seems obvious that a rapid, widespread vaccination campaign offers our nation the best chance of bringing the COVID-19 pandemic to a swift end. That observation is apparently lost on federal public health officials. Last week, the Centers for Disease and Control and Prevention and the Food and Drug Administration told healthcare providers to stop administering Johnson & Johnson's one-dose COVID-19 vaccine over concerns that the shot could cause blood clots in rare cases. Dr. Anthony Fauci, the head of National Institute of...

April 19, 2021 Multimedia, Policy Proposals, Resources, Value

Watch PRI's Dr. Wayne Winegarden discuss the importance of improving competitions for biosimilars to increase access to these high value medications for more patients on two "Bending the Cost Curve" panel discussions hosted by State of Reform. https://youtu.be/oJTD34j-E-Y https://youtu.be/hu8sWIn3u_A...

April 15, 2021 Policy Proposals

Lawmakers in Colorado are trying to open their state's borders to prescription drugs from abroad. In 2019, they green-lit imports from Canada. They're still working on a plan to implement that policy that can garner federal approval. Then last week, legislators approved a bill that would allow Coloradans to import prescription drugs from other countries in addition to Canada, assuming the feds give the okay. More than a dozen states are making similar moves to permit drug importation. The professed goal of these efforts is to...

April 14, 2021 Coronavirus-Alternate2, Issues

Citing “an abundance of caution,” the FDA on Tuesday recommended a “pause” in the administration of Johnson & Johnson’s COVID-19 vaccine.  The essence of that decision is that, as usual, federal regulators have put covering their derrieres above public health.  Let me explain. The decision was precipitated by six cases in the U.S. of a “rare and severe type of blood clot” in women between the ages of 18 and 48 who had received the vaccine.  Almost seven million shots of the...

April 14, 2021 Issues, Policy Proposals

Policymakers across the globe are attempting to vilify the same private companies that have been invaluable partners in the fight against the COVID-19 pandemic. If these efforts are successful, it will be patients who are harmed the most. Globally, the World Trade Organization (WTO) wants to waive the patent rights for the companies that developed effective COVID-19 vaccines in record breaking time. Here in the U.S., states as diverse as Arkansas, California, and Texas are considering policies that use the pandemic as an...